The association of selenium levels with markers of cardiovascular disease by Leonard, Kelsey
 
THE ASSOCIATION OF SELENIUM LEVELS WITH MARKERS OF 
CARDIOVASCULAR DISEASE 
 
 
 
 
 
 
 
by 
Kelsey Leonard 
BS Life Science, Pennsylvania State University, 2013 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Epidemiology 
Graduate School of Public Health in partial fulfillment 
of the requirements for the degree of 
Master of Science 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2016 
 
 ii 
UNIVERSITY OF PITTSBURGH 
Graduate School of Public Health 
 
 
This thesis was presented 
 
by 
 
Kelsey Leonard 
 
 
It was defended on 
April 20, 2016 
and approved by 
Thesis Advisor: 
Steven Belle, PhD, MScHyg, BA 
Professor 
Department of Epidemiology, Department of Biostatistics 
Graduate School of Public Health 
University of Pittsburgh 
 
Committee Members: 
Rhobert Evans, PhD, MBA, MS, BS, Associate Professor, Department of Epidemiology, 
Graduate School of Public Health, University of Pittsburgh 
 
 
Janet Catov, PhD, MS, BS, Associate Professor, Department of Obstetrics, Gynecology and 
Reproductive Services, Department of Epidemiology, Magee Women’s Research Institute, 
Graduate School of Public Health , University of Pittsburgh 
 
 
Deborah Hutcheson, DCN, MS, BS, Assistant Professor, Department of Sports Medicine and 
Nutrition, School of Health and Rehabilitation Sciences, University of Pittsburgh 
 
 
 
 
 
 
 
 iii 
  
Copyright © by Kelsey Leonard 
2016 
 
 iv 
Steven Belle, PhD, MScHyg, BA 
THE ASSOCIATION OF SELENIUM LEVELS WITH MARKERS OF 
CARDIOVASCULAR DISEASE  
Kelsey Leonard, MS 
University of Pittsburgh, 2016 
ABSTRACT 
Background: Oxidative stress is a key precursor to atherosclerosis, endothelial dysfunction and 
arterial stiffness, which are three mechanisms of the progression of cardiovascular disease (CVD).  
Selenium (Se) is an essential mineral that comprises at least 25 selenoproteins in humans.  Many 
of these selenoproteins play antioxidant roles that are crucial to arterial health and endothelial 
function.  A 2015 meta-analysis of observational studies proposed that CVD risk is significantly 
decreased only within the narrow selenium range of 55 to 145 µg/L.  
Methods: Data were previously collected from the Women and Infant Study of Healthy Hearts 
(WISH).  Serum samples from this study were analyzed to determine Se concentrations using 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS). The distribution of Se in this sample 
was examined as were linear and quadratic associations with carotid intima-media thickness 
(cIMT), pulse wave velocity (PWV) and flow mediated dilation (FMD).  Sub-group analyses 
were performed to examine these relationships within and outside of the reported beneficial 
range of Se status.  
Results:  Se concentrations ranged from 58 to 598 µg/L, with a median of 172 µg/L. No 
participants were deficient in Se, but 74% had selenium levels higher than 145 µg/L.  The 
distribution of Se was skewed left, so Se levels were natural log transformed for the analyses.   
Quadratic relationships between Se level and cIMT, FMD and PWV had better fit compared to 
 v 
linear relationships. There were no significant associations between Se status and cIMT (p=0.14), 
PWV (p=0.51) or FMD (p=0.51).  There was a significant linear relationship between Se levels 
greater than 145 µg/L and PWV (p=0.006).   
Conclusions: On average, the sample had good cardiovascular health and was relatively young to 
observe subclinical CVD progression.  There may be an inverse association between selenium 
status and pulse wave velocity, a marker of arterial stiffness.  This novel finding may lead to a 
greater understanding of the mechanisms of arterial stiffness, a major risk factor for CVD, which 
has great public health importance.  
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1.0  INTRODUCTION 
Selenium (Se), which was discovered in 1817, was historically considered a toxic element.  
In the 1930s, a link was determined between selenium deficiency and cardiomyopathies in 
livestock animals1.  Simultaneously, rural areas of China were plagued with endemic 
cardiomyopathies and osteoarthritis1.  These diseases were not attributed to Se deficiencies until 
the 1960s.  It is now understood that selenium is an essential trace mineral that is incorporated into 
the structure of at least 25 proteins in humans.  These proteins play integral roles in immune 
function, reproduction, brain function, thyroid function, metabolism and DNA synthesis2,3.  Both 
high and low Se levels have been observed to increase the risk of many adverse events including 
thyroid diseases, autoimmune diseases, cancers, and cardiovascular disease (CVD)3.    
Selenium plays a role in CVD, at least partly due to the antioxidant activity of numerous 
selenoproteins.  Oxidative stress is a key component in the development and progression of 
cardiovascular disease4,5.   Reactive oxygen species (ROS) are produced during the metabolism of 
oxygen and may be induced by environmental factors.  Antioxidants are needed to maintain the 
reduction-oxidation (redox) balance of the cell5.  When cells are unable to efficiently clear ROS 
the redox balance is skewed towards oxidation.  Oxidative stress results in the accumulation of 
oxidized lipids, and the activation of the immune response, inflammation and potentially cell 
death6.  Chronic oxidative stress creates a cellular environment susceptible to atherosclerosis, 
endothelial dysfunction and arterial stiffness5.  Selenoproteins are responsible for reducing ROS 
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and preventing oxidative stress in somatic cells throughout the body2.  However, the balance 
between oxidant species and antioxidant species must be maintained because critically low levels 
of ROS can inhibit cell signaling and function5.  
1.1 SELENIUM INTAKE AND METABOLISM 
Selenium intake varies widely geographically based on diet, supplementation and soil 
quality and fertilization.  The availability of selenium to plants varies due to soil speciation, pH, 
organic-matter content, and the presence of other ions2.  Acidic soil reduces uptake by plants.  
Selenium can complex with iron and aluminum in the soil, which renders it unavailable to plants7.   
The most common dietary sources of Se include organ meat, seafood, cereals, and grains2.  
Therefore, populations with high consumption of livestock animals and seafood generally have 
adequate Se intake.  On average, males consume more selenium than women6. Japan and North 
America have the highest mean intake of Se with men consuming about 120-140ug/day and 
women consuming about 80-120ug/day6,8.  China has the lowest intake of Se at an average of 30-
50ug/day6,8.  In the 1930’s an outbreak of cardiomyopathy, called Keshan disease, was discovered 
in areas of rural China1.  The etiology was unknown until population studies began in the 1960s 
which determined selenium deficiency as a likely cause1.  Due to low Se intake, diseases caused 
by selenium deficiencies, such as Keshan disease and Kashin-Beck disease, were endemic in China 
until the early 1990s1,2,9.  High-selenium crops and Se containing fertilizers are commonly used to 
increase the selenium content in plants and the livestock animals that consume them.   
  The intake of selenium is difficult to measure due to the geographic variation of soil and 
variability in diet trends across cultures.  The selenium content of crops varies widely depending 
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on where they are grown so it is difficult to construct standardized questionnaires that accurately 
assess intake.  Additionally, recall bias and portion size discrepancies prevent nutritional surveys 
from precisely measuring most micronutrients.  Thus, selenium levels are used as a more objective 
measure of selenium intake10.   There are many acceptable biospecimens from which to measure 
selenium status including serum, plasma, whole blood, hair, toenails and urine3,6,10,11.  Glutathione 
peroxidase activity and the expression of other selenoproteins have also been used as surrogate 
measures for selenium status3.  Serum, plasma and urine are able to reflect short term selenium 
status, while hair and toenail selenium reflect more long term concentrations3.   
Once ingested, selenocompounds are absorbed primarily through the duodenum10.   The 
efficiency of absorption and metabolism depends on the form of selenium ingested.  The two main 
organic forms of selenium are plant based selenomethionine and animal based selenocysteine2,10.  
Selenoproteins are proteins that contain the amino acid selenocysteine.  Selenocysteine (Sec) is 
the 21st amino acid and is coded for by the UGA codon, which is also a stop codon12,13,14.   
Therefore, selenoprotein mRNA contains a selenocysteine insertion sequence and other 
specialized translational machinery in the 3’ untranslated region of the mRNA. This allows 
translation to continue through the UGA codon12,13,14.   
Selenomethionine can be nonspecifically incorporated into other proteins in place of 
methionine9.  However, this form is less efficient in forming selenoproteins as it must first be 
converted to selenocysteine and further reduced to hydrogen selenide (H2Se)9,15. There are also 
inorganic sources of selenium which are commonly found in supplements, including selenite and 
selenate9.  These inorganic forms are already reduced, so they can be efficiently incorporated into 
selenoproteins.  Because of this efficiency, inorganic forms are more likely to cause toxicity 
compared to the organic molecules9, 16.  
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1.2 ROLES OF SELENOPROTEINS IN CARDIOVASCULAR DISEASE 
The current epidemiological evidence on the relationship between selenium and 
cardiovascular disease is conflicting (Appendix A).  Most clinical trials investigating the use of 
selenium supplementation have shown no improvements in cardiovascular risk factors17,18,19.  
However, the majority of supplementation studies have been conducted in samples with adequate 
selenium levels.   
Inadequate selenium concentrations and selenoprotein expression have been associated 
with an increased risk for oxidative stress, platelet aggregation and inflammation2,7,9,20,21.  Two 
meta-analyses have investigated the relationship between selenium levels and CVD in 
observational studies and clinical trials.  Both of these meta-analyses found that selenium status is 
significantly associated with decreased incidence of CVD, but the 2015 study found that CVD 
incidence was significantly reduced only for selenium levels between 55 and 145ug/L18,19.  Thus, 
a U-shaped association between selenium concentration and CVD morbidity and mortality may 
exist7,9,19.   
Selenoproteins are proteins that contain selenocysteine; there are over 25 known 
selenoproteins in the human body2,7.  Glutathione peroxidases (GPx) are a family of enzymes with 
numerous antioxidant functions.  There are five isoforms each with selenocysteine at their active 
center20.  Three isoforms have been implicated in CVD: GPx1 is found in the cytosol, GPx3 is 
found in plasma and GPx4 is found in phospholipid membranes9.   These enzymes function to 
remove hydrogen peroxide, lipid peroxides, phospholipid hydroperoxides, cholesterol 
hydroperoxides, superoxides and hydroxides from cells10,22,23.  By eliminating excess ROS, GPx 
enzymes play an integral role in regulating oxidative stress within the cell.  Due to its antioxidant 
properties in vascular tissues, GPx1 activity has been determined to be a strong predictor of 
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cardiovascular disease risk2,9,22,23.  In a cohort of individuals with coronary artery disease, 
erythrocyte GPx1 activity was significantly and inversely associated with the incidence of CVD 
events over a median follow up of 4.7 years23.  Functional variants of GPx3 have been associated 
with increased risk for stroke in both adolescents and young adults23,24.  Decreased expression of 
GPx3 has been shown to increase the risk of stroke in mice models25.  GPx4 is located in the 
membrane of endothelial cells and has been implicated in the reduction of lipid and phospholipid 
peroxidation within these membranes26,27.  
  Selenium is also a component of another family of enzymes responsible for balancing 
cellular redox processes, the thioredoxin reductases (TrxR).  Selenocysteine is present in the C-
terminus of TrxR enzymes28.  This group of enzymes is responsible for regenerating thioredoxins 
(Trx) in a nicotinamide adenine dinucleotide phosphate (NADPH) dependent mechanism17.  There 
are 3 isoforms of the Trx enzyme, which have multiple antioxidant functions and are involved in 
cell signaling processes9,28.  TrxR’s can directly reduce hydroperoxides, but also play an 
antioxidant role in the reduction of thioredoxin, which also serves as an antioxidant enzyme28.   
The Trx1/TrxR1 complex has been observed to reduce oxidative stress in cardiomyocytes in vitro9.   
Selenoprotein P (SEPP1) is another important selenoprotein in plasma.  Selenocysteine is 
contained in both the C-terminus and N-terminus of this protein28.  This selenoprotein is produced 
by the liver and acts as a transporter to supply extrahepatic tissues with selenium, but also can act 
as an antioxidant enzyme28.  There is evidence that SEPP1 inhibits insulin induced production of 
ROS and the AMP kinase signaling cascade7.  Other selenoproteins observed to be involved in 
cardiovascular disease progression are SelR and SelK.  SelR is responsible for reducing oxidized 
methionine on proteins and has been shown to be upregulated during times of cardiac stress in 
mice models9. SelK is located in the membrane of the endoplasmic reticulum and has been shown 
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to reduce oxidative stress in cardiomyocytes9.  SelK has also been observed to promote foam cell 
formation in vitro9.   
1.2.1 Atherosclerosis 
Atherosclerosis is a key mechanism in the development of CVD involving chronic 
inflammation, oxidized lipid accumulation in the vasculature and the formation and hardening of 
plaques5.  This is a natural process that occurs with aging, however genetics and lifestyle factors 
affect the rate at which atherosclerosis progresses.  Atherosclerotic progression can be quantified 
using carotid artery intima media thickness (cIMT).   
GPx1 is an antioxidant enzyme located in endothelial cells.  A cohort study in 2007 found 
that GPx1 activity was inversely related to atherosclerosis progression determined by cIMT29.  
Functional variants of GPx1 have been associated with increased cIMT in a study of individuals 
with Type 2 Diabetes22.  This indicates that there are genetic components that may interact with 
selenium status to modulate CVD progression.   
GPx3 is an antioxidant enzyme that circulates in plasma9,34.   This enzyme is able to reduce 
extracellular hydrogen peroxide and lipid hydroperoxides34.  It may prevent plasma LDL 
oxidation9. The oxidation of LDL-c in the endothelium is a key risk factor for developing 
atherosclerosis30.   
A known single nucleotide polymorphism (SNP) in the GPx4 gene alters the enzyme’s 
antioxidant function31.  Individuals with this SNP have increased lipid oxidation and increased 
adhesion of monocytes to endothelial cells, which are both important risk factors for 
atherosclerosis31.  In mice models, overexpression of GPx4 has been shown to protect against 
atherosclerosis5,25.   
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Interestingly, SelK has also been observed to to promote foam cell formation, which is an 
early step in the progression of atherosclerosis9.  In vitro, SelK has been observed to promote the 
expression of an integral membrane protein in macrophages, which leads to increased uptake of 
oxidized LDL cholesterol54.  
Studies involving selenium supplementation frequently produce null results.  This could 
be in part due to the reported U-shaped association between selenium status and morbidity.  
Evidence shows that selenium supplementation does not affect the progression of atherosclerosis32.  
Additionally, no association between toenail selenium status and cIMT or coronary artery 
calcification (CAC) was found in a cohort of 3112 Americans ranging from 20 to 32 years old33.   
1.2.2 Endothelial Dysfunction 
Endothelial dysfunction occurs when there is dysregulation of adhesion molecules, 
cytokines, chemokines and leukocytes in the endothelium30.  This dysregulation induces 
imbalances in signaling between vasoconstriction and vasodilation.  Nitric oxide (NO) is an 
important mediator of endothelium-dependent vasodilation, and also reacts rapidly with ROS.  
Decreased bioavailability of NO leads to domination by vasoconstriction30.  Oxidative stress in the 
endothelium increases its permeability and promotes adhesion events30.  Endothelial dysfunction 
can be quantified using flow mediated dilation (FMD), which measures the change in the diameter 
of an artery in response to blood flow.   
Studies in mouse models have shown that reduced GPx1 activity results in endothelial 
dysfunction, increased inflammation and structural vascular abnormalities17,22,23,29.  Insufficient 
GPx3 activity has been observed to increase platelet aggregation and NO responsiveness5.  
Functional variants in the GPx4 gene increase adhesion events in the endothelium, and these 
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polymorphisms have differential effects in Se deficient and Se replete environments31.   Trx and 
TrxR play a role in regulating the metabolism of nitric oxide (NO), which is crucial to endothelial 
vasodilation17.  There are no studies to our knowledge that have directly investigated the cross 
sectional association of selenium status and markers of endothelial function.   
1.2.3 Arterial Stiffness 
Arterial stiffness is characterized by the hardening of arteries.  This occurs when there is 
an imbalance between collagen and elastin proteins in the endothelium35.  This occurs naturally 
with aging and atherosclerosis, but is also influenced by genetic and lifestyle factors.  Arterial 
stiffness is a primary risk factor for increased systolic blood pressure (SBP).  It can be quantified 
using pulse wave velocity (PWV).  Arterial stiffness leads to higher PWV.   
There are very few existing studies that have investigated the relationship between 
selenium status and arterial stiffness.  In a cross sectional study of patients at high risk for CVD, 
those within the bottom 10% of selenium intake had significantly higher PWV compared to the 
rest of the cohort35.   There have been multiple RCTs that have shown reductions in arterial 
stiffness due to antioxidant supplementation, but few focus on selenium.  An RCT from 2010 
showed that an antioxidant supplement containing Se, Vitamin A, Vitamin E and Coenzyme Q10 
improved arterial elasticity compared the placebo in a population of individuals at risk for CVD53.  
However, it is impossible to decipher the individual effects of each component in the supplement.   
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1.2.4 Detriment of High Selenium Status 
Few studies have examined the high levels of Se that may increase the risk for CVD.  The 
strongest evidence for detrimental effects of high Se status focus on insulin signaling.  SEPP1 and 
GPx1 are both involved with insulin pathways2,28.  Insulin induces ROS production when it binds 
to adipocytes in order to activate the insulin signaling cascade2,28.  Both GPx1 and SEPP1 inhibit 
the production of ROS and therefore interfere with the insulin signaling cascade, which can lead 
to insulin resistance2,28.  In a study of pregnant women, there was a significant positive association 
between GPx1 activity and fasting plasma glucose, insulin, and homeostatic model assessment of 
insulin resistance36.  SEPP1 has been associated with hemoglobin A1C and fasting plasma glucose, 
which are measurements of glucose tolerance37.  Another study showed that Korean patients with 
Type 2 Diabetes had significantly increased SEPP1 mRNA levels compared to those with normal 
insulin sensitivity38.   
In the National Prevention of Cancer trial, participants were randomly assigned 200µg of 
selenium per day or placebo.  There was a significant increase in the incidence of Type 2 Diabetes 
Mellitus in participants who were within the highest tertile (>121.6 µg/L) of selenium status at 
baseline39.  It is well established that insulin resistance and Type 2 Diabetes are associated with an 
increased risk for CVD40. 
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2.0  METHODS 
2.1 SAMPLE  
 The sample used in this study is from the Women and Infant Study of Health Hearts 
(WISH) cohort which was comprised of 702 White and African American women who gave birth 
between 1997 and 2002 in Pittsburgh, PA41.  Women in WISH were recruited 4 to 12 years after 
giving birth to examine differences in subclinical atherosclerosis between women who had preterm 
births and those who had term births.  Markers of cardiovascular disease were measured using 
cIMT, FMD and PWV41.  Fasting blood samples were drawn for measurement of lipids and 
inflammatory markers.  Investigators found that women with prior preterm births had significantly 
higher mean systolic and diastolic blood pressure, LDLc, triglycerides, apolipoprotein B and lower 
HDLc.  Women with prior preterm births also had significantly higher CIMT than women with 
term births.  Having at least one preterm birth is associated with an increased risk of CVD.  These 
results suggest that the mechanism behind this could be related to chronic inflammation, and an 
earlier onset of atherosclerosis.    
A random sample of 49 cases of mothers with preterm births and 51 controls (mothers with 
term births) were chosen for the analysis.  A priori effect size calculations are shown in Appendix 
B.  With 100 samples, there was at least 80% power to detect an absolute value of a correlation 
coefficient of 0.28 or greater using a two-sided test with α=0.05.  
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2.2 CVD BIOMARKER ASSESSMENTS 
 Protocols for these assessments in WISH have been previously reported41.  Briefly, cIMT 
was measured at the baseline visit using B-mode ultrasound images of both the right and left distal 
common carotid artery, carotid bulb and internal carotid artery during diastole.  Specialized 
software was then used to detect the edges of the lumen-intima and media-adventia and obtain 
intima media thickness values at each site.  The mean values at each site were then averaged to 
obtain the mean IMT for each participant.  cIMT is positively associated with the risk of CVD.  
 FMD was measured after 10 minutes of supine rest using B-mode ultrasound images of 
the right brachial artery.  Ultrasound images were taken at rest and after 4 minutes of blood flow 
occlusion.  The diameter of the artery at both time points was determined using specialized 
software.  FMD was calculated by taking the percentage change in arterial diameters between the 
two time points.  FMD is inversely associated with CVD risk.  
PWV was measured by recording pressure waveforms in the right common carotid artery 
and right femoral artery simultaneously and calculating the distance between sites divided by the 
time the waveforms took to move between sites.  This was performed 10 times and the mean PWV 
was reported.  PWV is positively associated with the risk of CVD.  
2.3 SELENIUM ANALYSIS 
 Serum samples were frozen at -80°C from the original study date until used for this 
analysis.  The random sample of 49 cases and 51 controls from the WISH population was assayed 
for selenium detection using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) using a 
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Perkin-Elmer NeXION 300x ICP-MS (PerkinElmer Inc, Shelton, CT).  This method is commonly 
used for analysis of serum and plasma selenium.   The assays were completed at the University of 
Pittsburgh’s Department of Geology and Planetary Science.  Serum samples were thawed and 
100µL of sample was diluted with 1.9mL of nitric acid and 16 µL of an internal standard was 
added.  Samples were nebulized and introduced into the ICP plasma.  ICP-MS uses argon discharge 
at extreme temperatures averaging 5000-10000K to ionize the samples.  Results are presented in 
the accepted notation of µg/L.  This assay was performed masked as to whether samples came 
from cases or controls.   
2.4 STATISTICAL ANALYSIS 
 Descriptive statistics were calculated for baseline characteristics of the sample.  Mean 
values and standard deviations are reported for normally distributed continuous values.  Median 
values and the 25th and 75th percentile are reported for non-normally distributed continuous values.  
Frequencies and percentages are reported for categorical values. The distribution of selenium 
levels and markers of CVD were examined using the arithmetic mean, geometric mean, skewness, 
kurtosis and histograms.  Distributions of continuous measurements were examined for normality 
and natural log transformed when skewed left. Frequency distributions with normal density 
functions were drawn for selenium levels and the natural log transformation of selenium levels 
(Figures 1 and 2).  For variables with missing values, t-tests, Wilcoxon rank sum or chi square 
tests were used to determine whether differences of all other variables between those with the 
missing value and those without were statistically significant.  Linear and quadratic relationships 
were examined between Se levels and cIMT, PWV and FMD using linear regression.  Goodness 
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of fit was evaluated for both linear and quadratic relationships using R2 values and residual plots.  
To test the hypothesis that CVD biomarkers are associated with selenium within the range of 55 
to 145 µg/L, the same analyses were performed between selenium status and cIMT, PWV and 
FMD within and outside of this range.  All statistical analyses were carried out using SAS version 
9.4 (SAS Institute Inc., Cary, NC, USA).   
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3.0 RESULTS 
 Table 1. Demographic and clinical variables of sample at time of blood draw (N=100) 
Data Expressed as Mean(SD),  Median (25th, 75th percentile) or Number (%)   N Missing 
 
Race 
     African American  
     White 
 
28 (28.6) 
70 (71.4) 
  2 
Age (Years) 29.7(6.6)   2 
BMI (kg/m2) 28.9(7.5)   2 
Current Use of Blood Pressure Medication 6(6.1)   2 
Current Use of Statins 2(2.0)   2 
Diabetes 2(2.0)   2 
Current Smoker 30(30.6)   2 
Menopause 9(9.2)   2 
Preterm Birth of Child 49(49.0)   0 
Family History of Stroke 12(12.2)   2 
Vitamin/Supplement Use 46(46.9)   2 
Waist Circumference (cm) 95.6(16.7)   2 
Total Cholesterol (mg/dL) 191(39.8)   2 
LDL Cholesterol (mg/dL) 114(34.3)   2 
Triglycerides (mg/dL) 95.0(67.0,136.0)   2 
Diastolic Blood Pressure (mm Hg) 70.4(9.4)   2 
Systolic Blood Pressure (mm Hg) 109(12.6)   2 
Apolipoprotein B (mg/dL) 89.2(26.8)   2 
CRP (mg/L) 2.1(1.0, 6.3)   2 
Hemoglobin A1C (%) 5.1(0.5)   2 
IL-6 (pg/mL) 1.7(1.0, 2.7)   21 
Adiponectin (mg/L) 13.3(5.5)   2 
Flow Mediated Dilation (%) 7.1(4.8,10.9)   45 
Brachial Artery Diameter(mm) 3.4(0.8)   45 
Pulse Wave Velocity (m/s) 7.6(1.4)   16 
Carotid IMT (mm) 0.6(0.08)   12 
Total MET Hours per Week 8.6(3.5, 16.0)   2 
15 
3.1 DESCRIPTIVE STATISTICS 
Descriptive statistics for the sample at the time of blood draw are given in Table 1.    The 
mean age for the sample was 29.7 years.  The mean carotid IMT was 0.6 mm.  The median FMD 
was 7.1%.  The mean PWV was 7.6 m/s. LDL-c, CRP, IL-6, FMD and total MET hours per week 
had skewed distributions and were natural log transformed for analyses.  45 subjects had missing 
values for FMD, which was due to difficulty obtaining quality ultrasound images.  Those that have 
measurements for FMD were compared to those without measurements for FMD.  Student’s t-test 
was used for normally distributed means, χ2 tests for categorical variables and the Wilcoxon rank-
sum test was used to compare smoking pack years, total MET hours per week, IL-6, CRP, 
apolipoprotein B and waist circumference.  The only significant difference between the groups 
was the mean adiponectin values, which were 14.8 mg/dL and 11.5 mg/dL, respectively.  Since 
the two groups appeared to be similar, the relationship between FMD and selenium levels was 
analyzed using 55 subjects.   
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Figure 1. Distribution of Selenium status with normal density function 
 
 
Figure 2. Distribution of ln(Selenium) levels with normal density function 
 
17 
Table 2. Distribution of Selenium levels  
Percentile Selenium concentration 
(µg/L) 
Minimum 57.7 
25th Percentile 142.8 
Median 171.7 
75th Percentile 210.0 
Maximum 597.7 
Range  
     <55µg/L 0 (0%) 
     55-145 µg/L 26 (26%) 
     >145 µg/L 74 (74%) 
 
3.2  SELENIUM DISTRIBUTION 
  The selenium distribution in this sample was skewed left, therefore selenium 
concentrations were ln transformed for these analyses.    Figures 1 and 2 show the distributions of 
selenium levels and the ln transformed selenium levels respectively, with overlaid normal density 
functions.   The median selenium level in this sample was 171.7µg/L (Table 2).  This is a sufficient 
concentration for selenoprotein function, however this concentration is greater than the level 
shown to reduce cardiovascular disease risk18,19.   The minimum selenium level in this sample was 
57.7µg/L, which is within the range of values associated with low CVD risk18,19.  The meta-
analysis from 2015 found that the beneficial range for selenium status for cardiovascular health 
fell between 55-145µg/L, and only 26% of this sample fell within this range19 (Table 2).  The 
maximum selenium status was 597.7µg/L, this is an outlier, but is included in the analysis because 
it was not known to be inaccurate.  This extreme value could possibly be due to supplementation, 
18 
but could be due to measurement error.  Analyses excluding this outlier had similar results to the 
analyses in which it was included, so only the latter are reported.   
Table 3. Regression model examining quadratic trends between Selenium levels and cIMT, 
PWV and FMD  
N βl1 Pl βq2 Pq 
cIMT 88 0.58 0.14 -0.05 0.14 
PWV 84 3.95 0.57 -0.44 0.51 
FMD 55 2.17 0.53 -0.22 0.51 
1βl -regression coefficient for linear term, Pl- p value for linear term 
2βq -regression coefficient for quadratic term, Pq- p value for quadratic term 
Figure 3. Scatter plot of Selenium level and cIMT
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   Figure 4. Scatter plot of Selenium level and FMD 
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Figure 5. Scatter plot of Selenium level and PWV 
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  Figure 6. Scatter plot of Selenium levels >145 µg/L and PWV 
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3.3 ASSOCIATION BETWEEN SELENIUM LEVEL AND CIMT 
 Only 88 out of the 100 participants had measures for cIMT, which is positively correlated 
with CVD risk5. The scatter plot showing ln transformed selenium levels versus cIMT is shown in 
Figure 3.  The quadratic regression curve is overlaid on the scatter plot. Examination of linear and 
quadratic trends using linear regression shows that the quadratic relationship between ln(Se) and 
cIMT has better goodness of fit than the linear relationship, though the regression coefficient for 
the quadratic model is not significant (p=0.14).  This indicates that there is not a significant 
association between selenium concentrations and cIMT in this sample.   
3.4 ASSOCIATION BETWEEN SELENIUM LEVEL AND PWV 
Only 84 out of the 100 participants had measures for PWV, which is positively correlated 
with cardiovascular mortality35.  The scatter plot showing ln transformed selenium levels versus 
PWV is shown in Figure 4.  The quadratic regression curve is overlaid on the scatter plot. 
Examination of linear and quadratic trends using linear regression showed that the quadratic 
relationship between ln(Se) and PWV has better goodness of fit, though the regression coefficient 
for the quadratic model is not significant (p=0.51).  This indicates that there is not a significant 
association between selenium status and PWV in this sample.   
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3.5  ASSOCIATION BETWEEN SELENIUM LEVEL AND FMD 
 Only 55 of the 100 participants had measures for FMD, which is inversely associated with 
CVD risk30.    The scatter plot showing ln(Se) versus ln(FMD) is shown in Figure 5.  The quadratic 
regression curve is overlaid on the scatter plot.   Examination of linear and quadratic trends using 
linear regression showed that the quadratic relationship between ln(Se) and ln(FMD) has better 
goodness of fit, though the regression coefficient for the quadratic model is not significant 
(p=0.51).  This indicates that there is not a significant association between selenium levels and 
FMD in this sample.   
3.6 ANALYSES WITHIN AND OUTSIDE OF IDEAL SELENIUM RANGE 
 Only 26 of the 100 participants had selenium levels within the range of 55 to 145 µg/L 
(Table 2). There are no significant associations between Se levels and the CVD measures within 
the Se range of 55-145 µg/L.  The other 74 participants had selenium concentrations greater than 
145 µg/L.  There are not significant associations between selenium levels >145 µg/L and cIMT 
(n=65) or FMD (n=37).  The scatter plot showing ln transformed selenium status versus PWV in 
those with selenium >145 µg/L is shown in Figure 6.  The linear regression function is overlaid 
over the scatter plot.  Interestingly, for selenium levels greater than 145 µg/L, there is a significant 
negative linear relationship between ln(Se) and PWV (β=-1.58, p=0.006).   
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4.0  DISCUSSION 
 There are no significant associations between selenium status and either cIMT, PWV or 
FMD in this sample of 100 women.  Only 26% of the sample fell within the range of Se levels that 
is associated with a decreased risk of cardiovascular disease, the remaining majority of the sample 
had Se levels above 145 µg/L19.  There is no established cut point that defines Se deficiency, but 
studies of Keshan disease in China showed that the disease did not occur in communities where 
Se concentrations averaged 21 µg/L43.  Therefore, it can be assumed that no individuals were 
deficient in selenium, since the minimum Se status in the sample used for the current analysis was 
57.7 µg/L.  This supports previous research that North Americans, on average, have sufficient 
intakes of Se2,3,6,8.   
The results of these analyses do not support that Se is associated with CVD risk in this 
sample.  However, only 26 participants have Se levels in the range expected to reduce CVD risk. 
The CVD biomarkers indicate that there is low CVD risk, which limits the ability to detect a 
relationship between Se levels and cIMT, PWV and FMD.  In the sub-analyses examining the 
correlations within and outside of this range, there is a significant association only between Se 
levels above 145 µg/L and PWV.  This indicates that higher selenium levels are associated with 
lower PWV, which is associated with a lower risk for CVD.  This conflicts with the findings in 
previously published research and bears further examination18,19.   
The lack of a statistically significant association between Se and the CVD markers in this 
sample may be due to a lack of power.  Effect size calculations were computed based on the sample 
size of 100 individuals for which selenium levels could be measured.  However, only 88 
participants had measurements for cIMT, 84 for PWV, and 55 for FMD.  The observed correlations 
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between Se status and cIMT and FMD are close to zero.  The relationship between PWV and Se 
level is stronger, particularly within the subgroup of participants who have Se concentrations 
greater than 145 µg/L.   
This sample of women had a mean age of 29.7 years, which is a young group to study 
cardiovascular disease since age is positively associated with the risk of CVD44-46.   The sample 
also appears to have good cardiovascular health, with low blood pressure, total cholesterol and a 
low prevalence of diabetes.  A meta-analysis in 2013 described ideal cardiovascular health metrics 
for young adults with a mean age of 29.5 years.  Their ideal systolic blood pressure is 120 mmHg, 
ideal diastolic blood pressure is 80 mmHg and ideal total cholesterol is <200mg/dL44.  
 Because the sample used in this analysis was young and relatively healthy, measures of 
the three CVD markers are associated with minimal CVD risk.  The median FMD was 7.1%.  In a 
study of young, healthy Finnish adults with a mean age of 31.6 years, the mean FMD was 7.8%45.  
The mean PWV in this sample was 7.6m/s.  In a meta-analysis of healthy adult females with a 
mean age of 37, the mean PWV among was 7.7m/s47.  The mean cIMT was 0.6mm in this sample.   
A cohort of healthy young American adults with a mean age of 29.5 years was previously reported 
to have a mean cIMT of 0.67mm46.  PWV and IMT are positively associated with age, while FMD 
is inversely associated46.47,55.   Based on the previous literature of populations with similar age 
ranges, this sample, on average, had minimal CVD risk.  
The only significant association between selenium status and CVD is between selenium 
levels >145 µg/L and PWV.  Selenium concentrations may only be a predictor of CVD risk at 
older ages.  Additionally, the Zhang meta-analysis did not have sufficient evidence to examine the 
association of CVD risk and selenium status above 165 µg/L, but the relationship was null between 
145 and 165 µg/L19.  They hypothesized that the U-shaped association between Se levels and CVD 
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risk is true19.  These analyses show a possible beneficial relationship between higher Se status and 
arterial stiffness, which would not support the U-shaped association.  
This small pilot study has limitations.  The small sample size limits power to observe 
associations between selenium levels and the measures of CVD.  The sample has limited diversity, 
being only White and African American females.  The young age of the sample limits the ability 
to detect atherosclerosis, arterial stiffness and endothelial dysfunction.  Factors which may 
confound any associations were not adjusted for in the analysis.  
However, strengths of this study include the use of an objective measure of selenium status.  
CVD risk is examined in a young, fairly healthy sample, which can help to determine mechanisms 
for prevention.  This is the first study to examine the cross-sectional relationship between selenium 
status and cIMT, PWV and FMD in a healthy population. 
Cardiovascular disease is one of the top causes of morbidity and mortality worldwide44. It 
has been established that selenium levels, within a certain range, are associated with a lower risk 
of CVD18,19.  The field of CVD prevention and treatment would benefit from a greater 
understanding of the biological pathways that lead to arterial stiffness, endothelial function and 
atherosclerosis.  This study shows that higher Se concentrations may be associated with PWV, a 
marker of arterial stiffness.  Increased arterial stiffness is one of the primary risk factors for 
increased systolic blood pressure.  Because arterial stiffness is reversible, there may be a potential 
for therapeutic supplementation of selenium. 
Overall, this sample of women had adequate levels of selenium status.  When restricted to 
selenium concentrations greater than 145 µg/L, there is a significant inverse relationship between 
Se and PWV.  This association has not been examined in a healthy population previously so it may 
be useful to examine the relationship in larger studies with a more diverse population.  This 
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suggests many future directions.  The association between Se and PWV should be examined in 
older people and among individuals with higher risk for CVD.  This association should also be 
studied in male populations, as males have increased risk for CVD at younger ages compared to 
women.  It is also important to study these relationships in populations that have Se levels less 
than 55 µg/L.  There may be stronger associations with CVD risk when selenium concentrations 
are inadequate.  The quadratic trend between Se levels and CVD risk needs to be validated.  There 
are currently few studies that examine the cardiovascular risks and benefits of selenium 
supplementation.  The U-shaped association may not appear for individual markers of CVD, as is 
shown in this analysis with PWV.  There may also be other markers of CVD that may have stronger 
associations with selenium concentrations.  Additionally, there are known variants in the GPx1, 
GPx3 and GPx4 genes that affect CVD risk, so genotyping of these variants should also be 
encouraged in studies of cardiovascular health22,24,25,31.   
  
28 
APPENDIX A: PREVIOUS STUDIES OF SELENIUM STATUS AND CVD RISK 
Tables 4 and 5 contains a review of previous observational studies, RCTs and meta-
analyses of studies investigating selenium status or supplementation in association with various 
CVD risk factors. Table 4 contains studies with significant results and Table 5 contains studies 
with null results.   
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     Table 4. Selected Selenium studies with significant results 
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Table 5. Selected Selenium studies with null results 
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APPENDIX B: POWER AND EFFECT SIZE CALCULATIONS 
Effect size calculations were performed a priori with the assumptions of 100 samples, 2 sided 
α=0.05 for Pearsons’s correlation tests against the hypothesis ρ1=0.   
 
Table 6. Effect size calculations for Pearsons’s correlation coefficients 
Power |ρ1| 
0.99 0.4 
0.87 0.3 
0.52 0.2 
0.17 0.1 
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B.1 POST HOC POWER ANALYSIS 
 
Measures for the CVD markers were missing for some subjects, so power calculations were 
performed for Pearson’s correlation coefficient with the actual sample sizes for each measurement 
and two sided α=0.05.   
 
Table 7. Post-hoc Effect Size Calculations for Pearson Correlation Coefficients 
 N |ρ1| Power 
IMT 88 0.34 0.9 
IMT 88 0.29 0.8 
IMT 88 0.26 0.7 
PWV 84 0.34 0.9 
PWV 84 0.30 0.8 
PWV 84 0.27 0.7 
FMD 55 0.42 0.9 
FMD 55 0.37 0.8 
FMD 55 0.33 0.7 
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